{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:48:22Z","timestamp":1761630502495},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2283,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1111\/j.1365-2230.2008.02993.x","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T01:21:08Z","timestamp":1228958468000},"page":"469-475","source":"Crossref","is-referenced-by-count":7,"title":["Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice"],"prefix":"10.1093","volume":"34","author":[{"given":"L.","family":"Puig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ro\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Garc\u00eda-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Corella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Alomar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB1","first-page":"3073","article-title":"Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial","volume":"290","author":"Gordon","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB2","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","article-title":"A novel targeted T-cell modulator, efalizumab, for plaque psoriasis","volume":"349","author":"Lebwohl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archderm.141.1.31","article-title":"Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis","volume":"141","author":"Menter","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10227-005-0116-1","article-title":"Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I","volume":"9","author":"Pariser","year":"2005","journal-title":"J Cutan Med Surg"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2133.2006.07344.x","article-title":"Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial","volume":"155","author":"Dubertret","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB6","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1610-0387.2006.06111.x","article-title":"Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, phase III, placebo-controlled trial","volume":"4","author":"Sterry","year":"2006","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaad.2004.09.029","article-title":"Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial","volume":"52","author":"Leonardi","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2230.2008.02993.x-BIB8","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.jaad.2005.12.018","article-title":"Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial","volume":"54","author":"Gottlieb","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2230.2008.02993.x-BIB9","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1016\/j.jaad.2005.10.028","article-title":"Long-term management of plaque psoriasis with continuous efalizumab therapy","volume":"54","author":"Menter","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB10","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis - oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB11","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","article-title":"Current severe psoriasis and the rule of tens","volume":"152","author":"Finlay","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/09546630601121086","article-title":"Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice","volume":"18","author":"Berends","year":"2007","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB13","first-page":"587","article-title":"Etanercept and efalizumab for the treatment of psoriasis: a systematic review","volume":"24","author":"Woolacott","year":"2006","journal-title":"Health Technol Assess"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2230.2008.02993.x-BIB14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2133.2007.07765.x","article-title":"Long-term treatment of plaque psoriasis with efalizumab: an Italian experience","volume":"156","author":"Costanzo","year":"2007","journal-title":"Br J Dermatol"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2230.2008.02993.x-BIB15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2133.2007.07764.x","article-title":"The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital","volume":"156","author":"Antoniou","year":"2007","journal-title":"Br J Dermatol"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2230.2008.02993.x-BIB16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2133.2007.07766.x","article-title":"Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute","volume":"156","author":"Ferr\u00e1ndiz","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB17","first-page":"838","article-title":"Successful treatment of hand and foot psoriasis with efalizumab therapy","volume":"5","author":"Fretzin","year":"2006","journal-title":"J Drugs Dermatol"},{"issue":"Suppl. S2","key":"10.1111\/j.1365-2230.2008.02993.x-BIB18","article-title":"Phase IV study to evaluate the safety and efficacy of efalizumab for treatment of hand and foot plaque psoriasis. Poster P532 presented at the Annual meeting American Academy of Dermatology, Washington, DC, USA February 2-6, 2007","volume":"56","author":"Leonardi","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2310\/7750.2007.00006","article-title":"Efalizumab for the treatment of psoriatic arthritis","volume":"11","author":"Papp","year":"2007","journal-title":"J Cutan Med Surg"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00403-006-0694-9","article-title":"The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab","volume":"298","author":"Pincelli","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"10.1111\/j.1365-2230.2008.02993.x-BIB21","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2230.2008.02993.x-BIB22","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.jaad.2005.10.029","article-title":"Relapse, rebound, and psoriasis adverse events: an advisory group report","volume":"54","author":"Carey","year":"2006","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2230.2008.02993.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2230.2008.02993.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:27:03Z","timestamp":1676384823000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/34\/4\/469\/6624865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2230.2008.02993.x","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}